Compazine

(Prochlorperazine)

ApprovedSmall molecule

GGlaxo Dba Glaxosmithkline

Compazine is one of 150 small molecule programs targeting Headache. It is currently in Approved.

Indications

Total Trials

Active Trials

149

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Multiple MyelomaActive, not recruiting

MigraineActive, not recruiting

SchizophreniaActive, not recruiting

PapillomaActive, not recruiting

Nausea and VomitingPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

MigraineApproved

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

PapillomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Compazine

GGlaxo Dba Glaxosmithkline

Approved

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine5 trials

Intravenous Fluids in Pediatric Migraine

Unknown status·—·N/A·NCT06182098·134 enrolled

SPG Block for Acute Pediatric Migraine

Unknown status·NNewark Beth Israel Medical Center·Phase 3·NCT03984045·72 enrolled

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine

Terminated·AAlbert Einstein Healthcare Network·Phase 4·NCT01629329·93 enrolled

Show 2 more trials

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

Completed·WWake Forest University Health Sciences·Phase 3·NCT05967442·157 enrolled

Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

Completed·MMontefiore Medical Center·Phase 4·NCT02389829·127 enrolled

Nausea2 trials

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Completed·JJoseph Roscoe·Phase 3·NCT00475085·1,021 enrolled

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

Completed·GGary Morrow·Phase 3·NCT00020657

Nausea and vomiting2 trials

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department

Completed·EEmory University·Phase 2·NCT00590317·64 enrolled

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed·UUniversity of Rochester NCORP Research Base·Phase 3·NCT03367572·1,363 enrolled

Headache2 trials

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

Unknown status·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 3·NCT02779959·80 enrolled

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

Completed·UUniversity Medical Center of Southern Nevada·Phase 4·NCT02657031·54 enrolled

Multiple Myeloma1 trial

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

Withdrawn·KKoen van Besien·Phase 1·NCT05013437

5 more indications

Schizophrenia1 trial

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02600741·296 enrolled

Papilloma1 trial

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02858310·224 enrolled

Acute Mountain Sickness1 trial

Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness

Completed·CCHRISTUS Health·Phase 4·NCT06310642·30 enrolled

Ketorolac1 trial

Intranasal Ketorolac Trial

Terminated·WWashington University School of Medicine·Phase 2·NCT06083571·41 enrolled

Unspecified1 trial

Prochlorperazine vs Metoclopramide

Completed·MMontefiore Medical Center·Phase 4·NCT00364806·76 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

COMPAZINE

NDA NDA011000

Jan 1, 1982

COMPAZINE

NDA NDA011127

Jan 1, 1982

COMPAZINE

NDA NDA010571

Oct 6, 1999

COMPAZINE

NDA NDA021019

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Prochlorperazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prochlorperazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prochlorperazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021019). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Compazine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine5 trials

Nausea2 trials

Nausea and vomiting2 trials

Headache2 trials

Multiple Myeloma1 trial

Schizophrenia1 trial

Papilloma1 trial

Acute Mountain Sickness1 trial

Ketorolac1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News